Results 21 to 30 of about 2,579 (176)

Transplacental transfer of ravulizumab in a pregnant woman with neuromyelitis optica: a case report

BMJ Neurology Open
Background Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing autoimmune disease of the central nervous system (CNS). Management during pregnancy is challenging due to limited safety data for disease-modifying therapies.Case presentation ...
Anu Jacob, Azza Mahmoud, Luai Eldweik, Asia Mubashir   +3 more
doaj   +2 more sources

Ravulizumab: A Review in Generalised Myasthenia Gravis

Drugs, 2023
Ravulizumab (ULTOMIRIS®) is the first long-acting complement C5 inhibitor (administered intravenously every 8 weeks) to be approved in several countries globally, for adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive (AChR Ab+).
Connie Kang (7248215)
openaire   +3 more sources

Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications.

PLoS ONE
IntroductionComplement component 5 inhibitor therapies (C5ITs) for rare hematological, renal, and neurological diseases are associated with increased meningococcal infection risk. Robust risk mitigation measures include vaccination, drug safety programs,
Cynthia Carrillo Infante, Arshad Mujeebuddin   +1 more
doaj   +2 more sources

Ravulizumab exposure in early pregnancy

Annals of Hematology
Before complement inhibitors were available, pregnancy in women with paroxysmal nocturnal hemoglobinuria (PNH) was associated with considerable mortality, mainly due to thromboembolism.
Wolfgang Füreder, Sonja Granser, Andreas Repa, Alex Farr   +3 more
doaj   +3 more sources

Case Report: Fulminant meningococcus-meningitis under treatment with ravulizumab despite complete vaccination—a rare but severe complication [PDF]

Frontiers in Medicine
ObjectivesComplement C5 inhibitors such as ravulizumab are increasingly used for acetylcholine receptor–positive generalized myasthenia gravis (MG) but confer a relevant risk of invasive meningococcal infection.
Gábor Kozák, Gábor Kozák, Stefan Förster, Michael Haap, Reimer Riessen, Samuel Böhm-Gonzalez, Jan-Hendrik Stahl, Alexander Grimm, Ulf Ziemann, Ulf Ziemann, Siri Göpel, Josua Kegele, Annerose Mengel, Annerose Mengel, Katharina Feil, Katharina Feil   +15 more
doaj   +2 more sources

Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder [PDF]

Frontiers in Neurology
ObjectiveTo assess the pharmacokinetics and pharmacodynamics of the long-acting terminal complement 5 (C5) inhibitor ravulizumab in adults with anti-aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) in the phase 3, open-
Stephan Ortiz, Sean J. Pittock, Achim Berthele, Michael Levy, Ichiro Nakashima, Celia Oreja-Guevara, Celia Oreja-Guevara, Kerstin Allen, Yasmin Mashhoon, Becky Parks, Ho Jin Kim   +10 more
doaj   +2 more sources

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.

PLoS ONE, 2020
BackgroundEculizumab has transformed management of paroxysmal nocturnal hemoglobinuria (PNH) since its approval. However, its biweekly dosing regimen remains a high treatment burden.
John Devin Peipert, Austin G Kulasekararaj, Anna Gaya, Saskia M C Langemeijer, Susan Yount, F Ataulfo Gonzalez-Fernandez, Emilio Ojeda Gutierrez, Christa Martens, Amy Sparling, Kimberly A Webster, David Cella, Ioannis Tomazos, Masayo Ogawa, Caroline I Piatek, Richard Wells, Flore Sicre de Fontbrune, Alexander Röth, Lindsay Mitchell, Anita Hill, Karen Kaiser   +19 more
doaj   +3 more sources

Complement inhibitor therapy in atypical hemolytic uremic syndrome (aHUS): evaluating the economic impact of introducing eculizumab biosimilars in Germany [PDF]

BMC Nephrology
Background Eculizumab, a humanized monoclonal antibody, inhibits activation of complement component C5. For patients with atypical hemolytic uremic syndrome, the introduction of eculizumab has markedly improved survival, restoring life expectancy close ...
Isabell Kaufhold, Daniel Lewkowicz, Danila Seidel, Paul Thomas Brinkkoetter, Florian Kron   +4 more
doaj   +2 more sources

Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials

Kidney Medicine
Rationale & Objective: Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by complement dysregulation. Ravulizumab is a C5i approved for the treatment of aHUS. This analysis assessed long-term outcomes
Yoshitaka Miyakawa, Bradley P Dixon, Katherine Garlo   +2 more
exaly   +3 more sources

Case Report: COVID-19 unmasks factor H mutation-driven hemolytic uremic syndrome in a previously undiagnosed septuagenarian kidney transplant recipient [PDF]

Frontiers in Medicine
Thrombotic microangiopathy (TMA) after kidney transplantation presents a significant diagnostic and therapeutic challenge. Complement-mediated thrombotic microangiopathy (CM-TMA), caused by dysregulation of the alternative complement pathway, is ...
Michael Fink, Marion Pollheimer, Alexander Kirsch, Alexander R. Rosenkranz, Kathrin Eller, Max Schuller   +5 more
doaj   +2 more sources